HISTORY

Key Company Milestones

2012

♦ BioMedix Introduces BioMedix Advisory Services and Revenue Cycle Management

♦ BioMedix Named One of the 100 Best Companies to Work For

♦ BioMedix PADnet™ Surpasses One Half Million Completed Tests
 

2011

♦ BioMedix™ receives U.S. Patent for collaborative care business method.

♦ BioMedix™ launches TRAKnet™ PM practice management and EHR for primary care and sub-specialty practices.

♦ BioMedix™ becomes exclusive distributor of APMA Coding Resource Center.


2010

♦ TRAKnet™ Practice Management software receives complete ONC-ATCB 2011/2012 certification.

♦ John Romans: 2010 CA Podiatric Medical Association Corporate Citizen of the Year Award.

♦ Invited as participant to California P.A.D. Task Force by Office of Gov. Schwarzenegger.

♦ The number of patients tested using PADnet™+ exceeds 360,000.

♦ TRAKnet™ receives the APMA seal of acceptance.
♦ John Romans, CEO of BioMedix™ is awarded APMA's Executive Director's Award for his contributions in 2009.
♦ BioMedix™ earns certified partner status in Microsoft Partner Program.
 

2009
♦ BioMedix™ launches TRAKnet™ DPM Advanced Practice Management Solutions (formerly PodMed), an integrated solution for Practice Management, Electronic Health Records (EHR), inventory, scheduling, electronic script writing, billing, reporting and charting. TRAKnet™ DPM seamlessly integrates with PADnet™+ for a complete solution for Podiatric centers of excellence.

♦ BioMedix™ acquires Leum Software Solutions, Inc. and its Podiatry-focused Practice Management and Electronic Health Records software, PodMed.

♦ The number of patients tested using PADnet™+ exceeds 200,000.

♦ BioMedix™ launches PADnet™ Disease Management System (PDMS), a collaborative care program for hospitals and health systems.


2008
♦ BioMedix™ pilots PADnet™ Disease Management System (PDMS) to support collaborative care efforts in an integrated continuum of care.

♦The number of patients tested using PADnet™+ exceeds 65,000.

♦ BioMedix™ forms an exclusive partnership (REACH) with ev3, a global leader and technology provider for specialists treating a wide range of vascular diseases and disorders, to advance its mission of early detection and effective treatment of Peripheral Arterial Disease (P.A.D) and Chronic Venous Insufficiency (CVI).


2007
♦ In January, BioMedix™ introduces upgrade options for PADnet™+ for expanded in-office testing capabilities: Venous Edition (for the detection of CVI) and Post-Exercise (for enhanced detection of P.A.D.).

♦ BioMedix™ launches updated and improved software for vascular lab efficiency and accreditation, and vascular surgery outcomes: TRAKnet™ Lab and TRAKnet™  Outcomes.

♦ In April, the total number of patients tested using PADnet™ exceeds 35,000.

2006
♦ BioMedix™ joins 45 medical societies and associations in becoming a Corporate Member of the P.A.D. Coalition, a non-profit group dedicated to education and advocacy in promoting the early detection and treatment of Peripheral Arterial Disease.  The P.A.D. Coalition estimates that over 10 million Americans currently have P.A.D., and that without detection, 30% of these people will die of P.A.D.-related heart attack or stroke within five years. 

♦ The number of patients tested using PADnet™ exceeds 20,000. The 20,000th test is performed in a Family Practice medical clinic in North Carolina.


2005
♦ The American Podiatric Medical Association (APMA) awards the BioMedix™ PADnet™ solution its Seal of Approval. The Seal is designed to inform Podiatric physicians and consumers about quality, safety and effectiveness of medical products. 

♦ BioMedix™ receives 2005 Product Leadership Award for PADnet™ from Frost and Sullivan, a leading independent market research firm.

♦ The number of patients tested using PADnet™ exceeds 10,000.

♦ BioMedix™ introduces CustomLab SQL Edition software (now TRAKnet™ Lab), based on a client server architecture, which supports Microsoft SQL-server back end databases. Benefits include data encryption and password protection (HIPAA requirements), stability, and industry leading vascular program efficiencies in workflow, clinical documentation, billing and reporting.

2004
♦ BioMedix™ releases PADnet™ vascular diagnostic device to test for Peripheral Arterial Disease (P.A.D.). PADnet™+ is easy to use, clinically valuable, and provides fair financial return with medically-appropriate testing.  PADnet™ can be used by medical staff in primary and podiatric care settings and PADnet™ studies can be interpreted by vascular specialists via secure web links.

♦ BioMedix™ receives FDA marketing clearance for PADnet™ as a 510K equivalent predicate device. This breakthrough technology eliminates the need for Doppler, a technician dependent means of obtaining Ankle-Brachial Indexes (ABI).  Instead, PADnet™ uses oscillometric means—measuring oscillations caused by the arterial pressure pulse—to determine segmental blood pressures.  Combining ABI with Pulse Volume Recording (PVR) and internet tools, PADnet™ allows Primary Care Physicians and Podiatric Physicians to communicate remotely with vascular specialists for interpretation of test results and prescription for follow-up care.

♦ BioMedix™ releases version 4 of its proven Vascular Lab Management software, CustomLab™. This software supports data transfer from the entire line of GE LOGIQ series ultrasound imagers, including the LOGIQ 7, LOGIQ 700, LOGIQ 9; as well as the LOGIQ Book. With the push of a button, CustomLab™ can acquire study data from BioMedix™ test devices and duplex ultrasound imagers. This direct download saves data entry time and reduces errors in transcription.

♦ The Vascular Diagnostic Lab (VDL) product runs on the proven Windows XP Professional software platform—offering greater stability, networking support (for both wired and wireless networked computers) and patient record security.
♦ BioMedix™ merges with A&A Medical, developer of CustomLab™ software for vascular laboratory management and OTIS™ (Outcomes Tracking System) software (now TRAKnet™ Outcomes) for vascular surgery outcomes management.  These software programs made significant advances in ease-of-use and interoperability with diagnostic imaging and physiologic test equipment. CustomLab™ and OTIS™ became platforms for the development of PADnet™.


2003
♦ BioMedix™ transitions to the new ISO 9001:2000 Manufacturing Quality Standards and is recommended for certification to the new ISO Quality criteria by BSI Management Systems in its certification audit.


2002
♦ Chris Evert, former tennis star, hosts a BioMedix™ video to raise awareness of the under-diagnosed and under-treated problem of Peripheral Vascular Disease.


2001
♦ Sports commentator Pat Summerall hosts a two-minute television segment on Fox Cable News profiling BioMedix™.  BioMedix™ achieves ISO Certification and CE Marking for its Portable Vascular Lab (PVL) product.


1998
♦ BioMedix™ introduces the Vascular Diagnostic Lab (VDL), a bilateral simultaneous testing device for lower extremity arterial physiological testing. The VDL was the first physiologic test device to run on the Microsoft Windows operating system platform.


1997
♦ BioMedix™ is established in Minnesota’ Medical Alley to create innovative user-friendly solutions to detect Peripheral Vascular Disease.  The initial offerings are easy-to-use hardware and software for vascular laboratories. The BioMedix Portable Vascular Laboratory (PVL) and Vascular Report Generator (VRG) rapidly gain recognition for accuracy and usability.